Biological Safety Testing Market Size, Share, Growth, and Industry Analysis, By Type (Adventitious Agents Detection Test,Bioburden Testing,Cell Line Authentication and Characterization Tests,Endotoxin Tests,Residual Host Contaminant Detection Tests,Sterility Testing,Other Tests), By Application (Blood & Blood Products,Cellular & Gene Therapy Products,Stem Cell Products,Tissues & Tissue Products,Vaccines and Therapeutics), Regional Insights and Forecast to 2035

Biological Safety Testing Market Overview

The global Biological Safety Testing Market size is projected to grow from USD 5204.09 million in 2026 to USD 5838.47 million in 2027, reaching USD 14653.19 million by 2035, expanding at a CAGR of 12.19% during the forecast period.

The Biological Safety Testing Market encompasses the range of assays, instruments, consumables and services focused on ensuring safety, sterility, and purity of biological and biopharmaceutical products. In 2023, the global biological safety testing market was estimated at about USD 4.8 billion. Projections indicate that by 2033 the market could reach roughly USD 13.4 billion, reflecting extensive expansion across testing segments. North America accounted for over 36 % of the market share in 2023, making it the largest regional contributor. 

In the USA market specifically, the U.S. biological safety testing products & services domain recorded a size of about USD 1.44 billion in 2024. The reagents & kits segment in the U.S. contributed nearly 39.56 % share of that market. Endotoxin testing was a significant portion of U.S. testing demand, while the U.S. accounted for a dominant fraction of North America’s share — North America held 42 % share of the global market in 2024 and the U.S. drove much of that leadership.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: ~36 % share held by North America in 2024 driving global dominance
• Major Market Restraint: ~22.6 % share accounted by endotoxin testing limitations constraining flexibility
• Emerging Trends: ~39.7 % of market via reagents & kits reflects shift to consumables
• Regional Leadership: ~42 % of global share in 2024 by North America
• Competitive Landscape: ~39.56 % share of U.S. market by reagents & kits segment
• Market Segmentation: ~24.1 % of demand arises from vaccines & therapeutics application
• Recent Development: ~36 % share by North America in 2023 underlines consistent dominance

Biological Safety Testing Market Latest Trends

One of the most significant trends in the Biological Safety Testing Market is the continued dominance of the reagents & kits sub-segment, which commanded roughly 39.7 % share in 2023 and remains the backbone for testing throughput. Another trend is the increasing adoption of outsourcing of tests to contract research organizations, with service providers handling a growing share of bioburden, sterility and endotoxin testing.

Rapid microbiological methods (RMM) are being adopted in perhaps 10–15 % of new projects to reduce turnaround time. In many regions, regulatory expectations demand validation of non-animal test alternatives, pushing about 5–10 % of new assays toward in vitro or molecular-based approaches. Geographically, Asia-Pacific is registering strong uptake: in 2023 North America held ~36.2 % of the marke.

Biological Safety Testing Market Dynamics

DRIVER

"Rising demand for biologics and advanced therapies"

In many regions, the growth of biologics (such as monoclonal antibodies, recombinant proteins, cell-based therapies) has created surging demand for rigorous safety testing. For example, the vaccines & therapeutics application segment accounted for ~24.1 % of global testing demand in 2023.

RESTRAINT

"High cost and complexity of advanced safety assays"

Many advanced safety testing methods require high investment in instrumentation, validation, and skilled labor. For example, endotoxin assays and viral clearance protocols may take weeks or months and demand expensive reagents.

OPPORTUNITY

"Shift toward non-animal testing and rapid methods"

Many regulatory agencies now favor non-animal (in vitro, molecular) alternatives. A growing share—perhaps 5–10 % of new assay development budgets—is now devoted to non-animal endotoxin or sterility testing approaches. Adoption of rapid microbiological methods (RMM) is increasing in new contracts, with some labs dedicating up to 10–15 % of throughput to RMM. 

CHALLENGE

"Fragmented regulatory frameworks and standardization gaps"

Different national regulations and lack of harmonized standards pose a challenge for global players. For instance, assay validation requirements vary by region, forcing ~25 % of B2B contracts to include region-specific requalification. This leads to duplicated effort and cost escalation. 

Biological Safety Testing Market Segmentation

Segmentation by type and application divides the Biological Safety Testing Market into measurable categories to support B2B procurement decisions, with seven primary test types and five applications driving demand; examples include ~7 test types and ~5 application verticals, with each segment representing between ~5 % and ~22 % of activity and influencing purchasing cycles across ~1200+ testing labs globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Adventitious Agents Detection Test: Adventitious Agents Detection Test Market Size, Share and CAGR: The adventitious agents detection segment recorded an estimated market size of USD 275.4 million in 2024, representing about 5.7 % share of the broader safety testing market and showing an estimated CAGR of ~13.6 % for near-term forecasts.

Adventitious agents detection testing focuses on identifying unexpected viral, mycoplasma or extraneous agents in biological materials; typical workflows include ~6–12 assay types per project and turnaround times averaging ~7–21 days.

Top 5 Major Dominant Countries in the Adventitious Agents Detection Test Segment

• USA — Market Size USD 98.5 million, Market Share ~35.7 % and CAGR ~12.5 % for specialized adventitious testing demand in 2024.
• Germany — Market Size USD 27.5 million, Market Share ~10.0 % and CAGR ~11.0 % reflecting strong biologics QC activity in 2024.
• China — Market Size USD 55.1 million, Market Share ~20.0 % and CAGR ~15.0 % driven by increased biologics manufacturing in 2024.
• Japan — Market Size USD 24.8 million, Market Share ~9.0 % and CAGR ~9.5 % supported by vaccine and biologics testing in 2024.
• India — Market Size USD 13.8 million, Market Share ~5.0 % and CAGR ~16.0 % reflecting growing CRO and CDMO testing volumes in 2024.

Bioburden Testing: Bioburden Testing Market Size, Share and CAGR: The bioburden testing segment was estimated at USD 1.44 billion in 2024, corresponding to approximately 29.7 % share of total safety testing activity and an observed CAGR near ~14.5 % in recent market analyses.

Bioburden testing assesses viable microbial contamination on product surfaces and in solutions; common methods include membrane filtration and plate counts, with labs processing ~10,000–100,000 .

Top 5 Major Dominant Countries in the Bioburden Testing Segment

• USA — Market Size USD 518.4 million, Market Share ~36.0 % and CAGR ~13.0 % driven by high biologics manufacturing and device testing volumes in 2024.
• China — Market Size USD 288.0 million, Market Share ~20.0 % and CAGR ~16.0 % reflecting rapid industrial capacity increases in 2024.
• Germany — Market Size USD 144.0 million, Market Share ~10.0 % and CAGR ~11.0 % supported by strong medtech QC activity in 2024.
• Japan — Market Size USD 100.8 million, Market Share ~7.0 % and CAGR ~9.0 % driven by established pharma QC needs in 2024.
• India — Market Size USD 86.4 million, Market Share ~6.0 % and CAGR ~18.0 % as CDMOs expand bioburden capacity in 2024.

Cell Line Authentication and Characterization Tests: Cell Line Authentication and Characterization Tests Market Size, Share and CAGR: The cell line authentication segment was valued around USD 1.62 billion in 2023–2024 estimates, representing roughly 33.4 % of specialized testing demand with an observed CAGR near ~11–12 % in available analyses.

Cell line authentication and characterization encompasses STR profiling, karyotyping, mycoplasma screening and phenotype assays; laboratories perform ~5–15 authentication tests per cell bank and up to ~100 authentication events per product lifecycle.

Top 5 Major Dominant Countries in the Cell Line Authentication Segment

• USA — Market Size USD 648.0 million, Market Share ~40.0 % and CAGR ~10.5 % resulting from expansive R&D and biotech pipelines in 2024.
• UK — Market Size USD 129.6 million, Market Share ~8.0 % and CAGR ~9.0 % driven by academic and CRO testing workloads in 2024.
• Germany — Market Size USD 97.2 million, Market Share ~6.0 % and CAGR ~9.5 % tied to strong translational research in 2024.
• China — Market Size USD 259.2 million, Market Share ~16.0 % and CAGR ~14.0 % as domestic biotech adoption grows in 2024.
• Japan — Market Size USD 81.0 million, Market Share ~5.0 % and CAGR ~8.5 % from established pharma research activities in 2024.

Endotoxin Tests: Endotoxin Tests Market Size, Share and CAGR: Endotoxin testing held a dominant portion with an estimated share of ~21.5 % of the market and a calculated market size near USD 1.04 billion in 2024, with an indicative CAGR of ~11.0 % across recent reports.

Endotoxin testing—historically LAL/gel clot or chromogenic methods—accounts for large consumables spend, with reagent kits representing ~40 % of segment revenues and laboratories executing ~100–1,000 .

Top 5 Major Dominant Countries in the Endotoxin Tests Segment

• USA — Market Size USD 395.2 million, Market Share ~38.0 % and CAGR ~10.0 % reflecting high biologics QC throughput in 2024.
• China — Market Size USD 208.0 million, Market Share ~20.0 % and CAGR ~14.0 % as domestic fill–finish capacity grows in 2024.
• Germany — Market Size USD 104.0 million, Market Share ~10.0 % and CAGR ~9.5 % with strong in-country pharma testing in 2024.
• Japan — Market Size USD 62.4 million, Market Share ~6.0 % and CAGR ~8.5 % due to vaccine and biologics QC in 2024.
• India — Market Size USD 52.0 million, Market Share ~5.0 % and CAGR ~16.0 % as CDMO endotoxin testing demand rises in 2024.

Residual Host Contaminant Detection Tests: Residual Host Contaminant Detection Tests Market Size, Share and CAGR: Residual host contaminant detection (host cell proteins, DNA) is estimated at roughly USD 320–380 million in 2024, representing about 6–8 % share of safety testing and showing typical CAGRs of ~12 % in specialist reports.

Residual host contaminant testing leverages ELISA, mass spectrometry and qPCR platforms; average analytical runs per program are ~10–50 assays per product lot with method development often consuming ~20–30 % of early testing budgets in 2023–2024.

Top 5 Major Dominant Countries in the Residual Host Contaminant Detection Tests Segment

• USA — Market Size USD 128.0 million, Market Share ~34.0 % and CAGR ~11.0 % for host-residual detection services in 2024.
• China — Market Size USD 64.0 million, Market Share ~17.0 % and CAGR ~15.0 % tied to upstream process testing in 2024.
• Germany — Market Size USD 32.0 million, Market Share ~8.5 % and CAGR ~9.5 % due to strong biologics QC practices in 2024.
• Japan — Market Size USD 25.6 million, Market Share ~6.8 % and CAGR ~8.0 % with established analytical labs in 2024.
• India — Market Size USD 19.2 million, Market Share ~5.0 % and CAGR ~17.0 % as contract test volumes increase in 2024.

Sterility Testing: Sterility Testing Market Size, Share and CAGR: Sterility testing represented an estimated USD 580–650 million in 2024, about 12–14 % share of total safety testing activity, with typical CAGR estimates near ~11–12 % in contemporary market reports.

Sterility testing uses direct inoculation and membrane filtration methods, often requiring lot-release testing with sample sizes upwards of ~3–10 units per lot and average assay times ranging from ~14–28 days for conventional methods in 2024.

Top 5 Major Dominant Countries in the Sterility Testing Segment

• USA — Market Size USD 234.0 million, Market Share ~36.0 % and CAGR ~10.5 % given high sterile manufacturing volumes in 2024.
• China — Market Size USD 104.5 million, Market Share ~16.0 % and CAGR ~15.0 % reflecting scale-up of sterile fill–finish in 2024.
• Germany — Market Size USD 65.4 million, Market Share ~10.0 % and CAGR ~9.0 % with established medtech and pharma sterile QC in 2024.
• Japan — Market Size USD 46.4 million, Market Share ~7.0 % and CAGR ~8.0 % supported by vaccine production in 2024.
• India — Market Size USD 36.0 million, Market Share ~5.5 % and CAGR ~16.5 % as sterile CDMO capacity expands in 2024.

BY APPLICATION

Blood & Blood Products: Blood & Blood Products Application: The blood & blood products application accounted for roughly 8–10 % of biological safety testing demand with a 2024 market contribution near USD 380–485 million and observed CAGR estimates around ~10–12 % in specialized analyses.

Testing for blood products includes pathogen screening, endotoxin, and residual contaminants, with sample volumes typically in the hundreds to thousands per month and per-test costs varying by method and region.

Top 5 Major Dominant Countries in the Blood & Blood Products Application

• USA — Market Size USD 171.3 million, Market Share ~35.5 % and CAGR ~9.5 % reflecting robust transfusion and plasma screening volumes in 2024.
• Germany — Market Size USD 38.0 million, Market Share ~8.0 % and CAGR ~8.0 % with regulated donor screening programs in 2024.
• China — Market Size USD 57.6 million, Market Share ~12.0 % and CAGR ~13.5 % as national blood services scale testing in 2024.
• Japan — Market Size USD 28.5 million, Market Share ~6.0 % and CAGR ~7.5 % due to established plasma fractionation QC in 2024.
• India — Market Size USD 22.8 million, Market Share ~4.7 % and CAGR ~15.0 % as screening labs expand in 2024.

Cellular & Gene Therapy Products: Cellular & Gene Therapy Products Application: The cell and gene therapy application contributed approximately 12–15 % of testing demand in 2024 with an estimated market contribution of USD 600–730 million and CAGRs in the ~12–15 % band reported across studies.

Cell and gene therapy testing requires specialized sterility, adventitious agent, potency and characterization assays; programs typically involve ~50–200 bespoke tests per IND/CTA .

Top 5 Major Dominant Countries in the Cellular & Gene Therapy Products Application:

• USA — Market Size USD 300.0 million, Market Share ~40.0 % and CAGR ~12.0 % given concentrated clinical programs and manufacturing in 2024.
• Germany — Market Size USD 54.0 million, Market Share ~7.2 % and CAGR ~11.0 % based on advanced cell therapy clusters in 2024.
• China — Market Size USD 90.0 million, Market Share ~12.0 % and CAGR ~16.0 % as domestic trials and manufacturing expand in 2024.
• Japan — Market Size USD 66.0 million, Market Share ~8.8 % and CAGR ~10.0 % due to supportive regenerative medicine frameworks in 2024.
• UK — Market Size USD 36.0 million, Market Share ~4.8 % and CAGR ~11.5 % with academic-industry translational programs in 2024.

Tissues & Tissue Products: Tissues & Tissue Products Application: Tissue and tissue products testing comprised approximately 6–8 % of testing demand with a 2024 estimated contribution near USD 300–390 million and reported CAGRs around ~9–11 % in specialized reports.

Top 5 Major Dominant Countries in the Tissues & Tissue Products Application:

• USA — Market Size USD 120.0 million, Market Share ~33.0 % and CAGR ~9.0 % due to transplant screening volumes in 2024.
• Germany — Market Size USD 36.0 million, Market Share ~10.0 % and CAGR ~8.0 % with regulated tissue banks in 2024.
• China — Market Size USD 45.0 million, Market Share ~12.0 % and CAGR ~14.0 % as tissue donation programs expand in 2024.
• Japan — Market Size USD 24.0 million, Market Share ~6.5 % and CAGR ~7.5 % with organized transplant centers in 2024.
• India — Market Size USD 18.0 million, Market Share ~5.0 % and CAGR ~15.5 % given growing tissue processing activity in 2024.

Vaccines and Therapeutics: Vaccines and Therapeutics Application: Vaccines and therapeutics formed the largest application share at about 24.1 % of testing demand in 2023–2024, equating to an estimated segment size near USD 1.17–1.35 billion and showing CAGRs typically cited near ~11–13 % in market analyses.

Top 5 Major Dominant Countries in the Vaccines and Therapeutics Application:

• USA — Market Size USD 445.2 million, Market Share ~33.0 % and CAGR ~11.0 % driven by vaccine development and biologics manufacturing in 2024.
• China — Market Size USD 236.7 million, Market Share ~17.5 % and CAGR ~15.0 % reflecting major vaccine production scale-up in 2024.
• Germany — Market Size USD 118.8 million, Market Share ~8.8 % and CAGR ~9.5 % with established therapeutics testing in 2024.
• India — Market Size USD 94.8 million, Market Share ~7.0 % and CAGR ~16.0 % as vaccine API and fill–finish expand in 2024.
• Japan — Market Size USD 88.0 million, Market Share ~6.5 % and CAGR ~8.5 % due to domestic vaccine programs in 2024.

Biological Safety Testing Market Regional Outlook

Regional performance shows North America, Europe, Asia-Pacific, Middle East & Africa as primary markets with diversified demand; North America held ~36–42% share in 2023–2024, Europe ~18–22%, Asia-Pacific ~20–28%, and MEA ~4–6% across multiple reports, with >1,200 testing labs active globally and regional deployment rates varying by 5–20% year-on-year. 

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

The North America region dominated biological safety testing demand, accounting for approximately 36.5–42.0% share in 2023–2024 and representing the largest concentration of testing capacity, clinical programs and CDMOs across ~1,000+ accredited labs. 

North America Market Size, Share and CAGR: In one estimate, North America recorded a market size near USD 1.7–2.0 billion in 2024, representing ~36–42% share and an indicative CAGR near 11–14% in published forecasts (30–35 words).

North America - Major Dominant Countries in the “Biological Safety Testing Market”

• USA — The United States led regional demand with an estimated market size near USD 1.5 billion in 2024, representing ~75–80% of North America’s share and an indicative CAGR around 11–14% in many forecasts. 
• Canada — Canada contributed roughly 4–6% of global demand in 2024, with market size estimates near USD 200–550 million and notable growth rates cited in regional studies between ~10–13%. 
• Mexico — Mexico accounted for about 1–2% of global testing volumes in 2024, with market size estimates near USD 40–80 million and regional growth potential cited at ~10–15% in projections. 
• Puerto Rico (U.S. territories & clusters) — Puerto Rico’s contract manufacturing and QC hubs represented ~1–3% of North American testing throughput in 2024, with localized capacity increases of ~5–10% annually. 
• Other North America (Caribbean clinical sites) — Smaller North American markets together made up ~1–3% of regional volume in 2024, with expansion in specialized testing by ~5–8% year-on-year. 

Europe

Europe contributed a significant share—commonly reported between ~18% and ~22% of global biological safety testing market activity in 2023–2024—driven by established pharma clusters in Germany, UK, France and other EU states and by >700 accredited labs handling multi-modal testing. 

Europe Market Size, Share and CAGR: Europe’s market was estimated in several reports at roughly USD 0.9–1.2 billion in 2024, representing ~18–22% share and projected growth rates often cited near 9–12% in leading analyses (30–35 words).

Europe - Major Dominant Countries in the “Biological Safety Testing Market”

• Germany — Germany ranked top in Europe with an estimated ~10–12% global share equivalent and market size near USD 100–140 million in 2024, with stable annual growth cited around ~8–11%. 
• United Kingdom — The UK represented roughly ~7–9% of European testing demand in 2024, with market size estimates near USD 80–110 million and reported growth near ~9–12% in studies. 
• France — France contributed about ~4–6% of global activity in 2024 with market size estimates near USD 50–90 million and regional growth rates near ~8–11%. 
• Italy — Italy accounted for ~3–5% of European volumes in 2024 with market size estimates near USD 40–70 million and growth referenced at ~7–10% in specialist reports. 
• Spain — Spain’s testing volumes comprised ~2–4% of Europe in 2024 with market size near USD 30–60 million and growth expectations of ~7–10% regionally. 

Asia-Pacific

Asia-Pacific has emerged as a major growth region with reported shares ranging from ~20% to ~28% in 2023–2024, buoyed by China, India, Japan and Southeast Asia where accelerated biomanufacturing and CDMO expansion have increased testing volumes significantly. 

Asia-Pacific Market Size, Share and CAGR: In regional estimates, Asia-Pacific’s market size was near USD 0.9–1.4 billion in 2024, equating to ~20–28% share with forecast growth rates commonly cited between ~12–17% in multiple market analyses (30–35 words).

Asia - Major Dominant Countries in the “Biological Safety Testing Market”

• China — China led APAC with an estimated share near ~12–18% of global activity and market size approximations of USD 200–350 million in 2024, with pronounced expansion in local CDMO testing capacity. 
• Japan — Japan represented ~6–8% of global testing volumes in 2024 with market size near USD 80–120 million and strong demand for vaccine and biologics QC services. 
• India — India accounted for ~4–6% of global safety testing in 2024 with market size estimates near USD 50–120 million and rapidly increasing outsourcing volumes from domestic biopharma. 
• Australia — Australia’s share was ~1–2% of global testing in 2024 with estimated market size near USD 20–40 million and stable growth in clinical and vaccine testing. 
• South Korea — South Korea accounted for ~1–2% of APAC volumes in 2024 with market size near USD 20–50 million and increasing cell therapy testing demand. 

Middle East & Africa (MEA)

MEA held a smaller but strategic portion of global testing activity—commonly reported between ~4% and ~6% in 2023–2024—driven by government vaccination programs, regional reference labs, and increasing CDMO interest, with capacity concentrated in Gulf states and South Africa. 

Middle East & Africa Market Size, Share and CAGR: MEA’s market size was estimated near USD 150–300 million in 2024, representing ~4–6% share with projected growth rates often referenced around ~8–12% in regional forecasts (30–35 words).

Middle East and Africa - Major Dominant Countries in the “Biological Safety Testing Market”

• South Africa — South Africa led MEA with roughly ~1.2–1.8% of global testing volumes in 2024 and market size near USD 30–60 million, with expanding laboratory networks and reference testing demand. 
• Saudi Arabia — Saudi Arabia represented ~0.8–1.5% of global activity in 2024 with estimated market size near USD 20–50 million and targeted investments in biotech QC infrastructure. 
• United Arab Emirates — UAE contributed ~0.5–1.2% of MEA testing in 2024 with market size near USD 10–30 million and growing hub status for regional CRO services. 
• Egypt — Egypt accounted for ~0.4–0.8% of global testing in 2024 with market size near USD 8–20 million and expanding public health testing programs. 
• Kenya — Kenya represented ~0.2–0.5% of global volumes in 2024 with market size near USD 4–12 million and growing regional diagnostic lab capacities. 

List of Top Biological Safety Testing Market Companies

• Cytovance Biologics
• TOYOBO Co Ltd
• MilliporeSigma
• Charles River Laboratories International, Inc.
• VIRUSURE
• Lonza Group AG
• SGS SA
• Toxikon Corporation
• WuXi Biologics (Cayman), Inc.
• Creative Biogene
• Avance Biosciences
• Samsung BioLogics
• BSL Bio service Scientific Laboratories GmbH

Top Two Companies highest market share

• Charles River Laboratories International, Inc. — Charles River is consistently cited among the top two market leaders and is reported to occupy an estimated ~10–15% share of the global biological safety testing market, with >300 global lab and service sites and hundreds of CRO partnerships as of 2024–2025. 
• MilliporeSigma (Merck KGaA Life Science business) — MilliporeSigma is frequently listed among the other top-one/two players and is reported to command an estimated ~8–14% share of the market, supported by a multi-site biosafety testing network and major capacity investments announced between 2023–2024. 

Investment Analysis and Opportunities

Investment flows into the Biological Safety Testing Market accelerated in 2023–2025, with facility expansion announcements and capital projects representing notable capacity additions: examples include multi-hundred-million euro investments and new test sites added in 2023–2024, and >200 new accredited testing labs opened or expanded across key regions in 2024–2025. Outsourcing trends show that contract research organizations and CDMOs now handle roughly 25–35% of routine safety testing volumes in mature markets, while top-tier reagent and kit spend accounts for approximately 35–45% of product spend across labs. For B2B investors, opportunities cluster around three areas: (1) capacity expansion in Asia-Pacific where regional shares rose by ~5–10 percentage points between 2020 and 2024, (2) investments in rapid microbiological methods and non-animal assays which account for ~5–15% of new method budgets.

New Product Development

New product development in the biological safety testing domain in 2023–2025 emphasized faster assays, non-animal alternatives and integrated analytics: notable innovations include validated all-in-one genetic stability assays, consolidated biosafety testing suites, and dedicated cell and gene therapy testing panels introduced across multiple providers. In 2024, at least one leading supplier launched an all-in-one genetic stability assay that reduced validation steps by an estimated 30–50% for typical cell bank programs, and several firms added pre-configured LIMS integrations that cut report turnaround by ~20–40% for subscribers. Rapid microbiological methods (RMM) and molecular-based sterility techniques were added to service menus by ~15–25% of mid-tier and large CROs between 2022 and 2025 .

Five Recent Developments 

• MilliporeSigma (Merck) biosafety facility investments (2023–2024): Merck announced and opened multi-site biosafety testing investments including a €290 million facility project and regional site upgrades that expanded global testing capacity and centralized analytical development in multiple locations. 
• MilliporeSigma Aptegra genetic stability assay launch (2024): MilliporeSigma launched the Aptegra™ all-in-one genetic stability assay in 2024, a validated method using whole-genome sequencing approaches that reduced conventional genetic stability testing steps by an estimated 30–50% in pilot programs. 
• Charles River advanced therapy and collaboration programs (2024–2025): Charles River expanded its advanced therapy offerings with a dedicated incubator and multiple collaboration announcements in 2024–2025, increasing early-stage cell therapy service touchpoints by >20% and accelerating access to cell therapy test workflows. 
• Eurofins / BSL BIOSERVICE integration and consolidation activity (2023–2024): The viral testing and biologics safety segments saw consolidation as BSL BIOSERVICE was folded into larger analytics networks.
• Samsung BioLogics expansion of testing and CDMO services (2023–2025): Samsung BioLogics completed Plant 4 and accelerated its Plant 5 timeline, while launching preclinical testing and clinical planning services in 2024–2025. 

Report Coverage of Biological Safety Testing Market

This report covers the Biological Safety Testing Market across seven test-type segments and five application verticals, profiling ~50+ leading vendors and 1,200+ testing laboratories active globally as of 2024–2025, and includes regional breakdowns for North America, Europe, Asia-Pacific and MEA. The scope includes product categories (reagents & kits, instruments, consumables), service types (outsourced testing, in-house QC support), and platform innovations (RMM, molecular assays, non-animal methods) with quantitative snapshots: for example, reagent & kits accounted for ~35–40% of segment spend and vaccines & therapeutics contributed ~24% of application demand in recent years.

The report offers detailed segmentation by type and application with per-segment market sizing and share estimates, top-5 country profiles per segment, and buyer-centric insights for B2B procurement teams (including vendor selection matrices, contract lead-time benchmarks and sample throughput metrics: average lab throughput ranges from ~10,000 to >100,000 samples per year by lab tier). 

Biological Safety Testing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5204.09 Million in 2026
Market Size Value By	USD 14653.19 Million by 2035
Growth Rate	CAGR of 12.19% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Adventitious Agents Detection Test Bioburden Testing Cell Line Authentication and Characterization Tests Endotoxin Tests Residual Host Contaminant Detection Tests Sterility Testing Other Tests By Application : Blood & Blood Products Cellular & Gene Therapy Products Stem Cell Products Tissues & Tissue Products Vaccines and Therapeutics
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample